Regeneron to Report Third Quarter 2022 Financial and Operating Results and Host Conference Call and Webcast on November 3, 2022PRNewsWire • 10/04/22
Regeneron (REGN) Recently Broke Out Above the 20-Day Moving AverageZacks Investment Research • 10/04/22
Aflibercept 8 mg Positive Pivotal Results in Diabetic Macular Edema and Wet Age-Related Macular Degeneration Presented at AAOPRNewsWire • 09/30/22
Dupixent® (dupilumab) Approved by FDA as the First and Only Treatment Indicated for Prurigo NodularisPRNewsWire • 09/28/22
Intellia and Regeneron Announce Initial Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) AmyloidosisPRNewsWire • 09/16/22
Positive Dupixent® (dupilumab) Phase 3 Data in Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis Published in The LancetPRNewsWire • 09/15/22
Alnylam and Regeneron Report Promising Data from Ongoing Phase 1 Study of ALN-HSD in NASH Patients and Healthy VolunteersBusiness Wire • 09/15/22
Regeneron and Alnylam Report Promising Data from Ongoing Phase 1 Study of ALN-HSD in NASH Patients and Healthy VolunteersPRNewsWire • 09/15/22
Regeneron Pharmaceuticals, Inc. (REGN) CEO Leonard Schleifer Presents at Morgan Stanley 20th Annual Global Healthcare Conference (Transcript)Seeking Alpha • 09/12/22
Positive Neoadjuvant Libtayo® (cemiplimab) Monotherapy Data in Resectable Cutaneous Squamous Cell Carcinoma Presented at ESMO and Published in NEJMPRNewsWire • 09/12/22
Fianlimab (LAG-3 Inhibitor) Combined with Libtayo® (cemiplimab) Demonstrates Greater than 60% Response Rates in Two Independent Cohorts of Patients with Advanced Melanoma Naïve to PD-1 or PD-L1 InhibitorsPRNewsWire • 09/12/22
Novel Regeneron Bispecific Antibodies Show Encouraging Anti-tumor Activity in Two Advanced Solid TumorsPRNewsWire • 09/10/22
